Veru (VERU) Stock Rating Upgraded by ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Veru (NASDAQ:VERU) from a hold rating to a buy rating in a research report report published on Friday, ValuEngine reports.

A number of other analysts have also weighed in on VERU. Zacks Investment Research raised shares of Veru from a sell rating to a buy rating and set a $1.50 target price on the stock in a report on Tuesday, February 19th. CIBC assumed coverage on shares of Veru in a report on Wednesday, March 20th. They set an outperform rating and a $5.00 target price on the stock. HC Wainwright reaffirmed a buy rating and set a $4.50 target price on shares of Veru in a report on Wednesday, January 23rd. Maxim Group set a $6.00 target price on shares of Veru and gave the stock a buy rating in a report on Thursday, February 14th. Finally, Oppenheimer assumed coverage on shares of Veru in a report on Tuesday, March 19th. They set an outperform rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Veru currently has a consensus rating of Buy and an average target price of $4.40.

Veru stock opened at $1.60 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.30 and a current ratio of 1.58. The company has a market cap of $100.37 million, a P/E ratio of -4.10 and a beta of 0.88. Veru has a 1-year low of $1.18 and a 1-year high of $2.37.

Veru (NASDAQ:VERU) last posted its earnings results on Wednesday, February 13th. The company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. The business had revenue of $6.37 million for the quarter, compared to analyst estimates of $9.71 million. Veru had a negative net margin of 111.10% and a negative return on equity of 60.83%. Research analysts expect that Veru will post -0.19 EPS for the current year.

In other news, insider Mitchell Shuster Steiner sold 49,899 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $1.53, for a total value of $76,345.47. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders bought 38,681 shares of company stock worth $53,206 and sold 109,545 shares worth $163,245. 29.50% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of VERU. Dimensional Fund Advisors LP increased its holdings in shares of Veru by 328.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 102,909 shares of the company’s stock worth $146,000 after buying an additional 78,909 shares during the last quarter. Vanguard Group Inc boosted its stake in shares of Veru by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock valued at $1,704,000 after purchasing an additional 13,650 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Veru by 9.3% in the 4th quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after purchasing an additional 10,956 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Veru by 115.4% in the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after purchasing an additional 115,506 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Veru in the 1st quarter valued at $95,000. 8.75% of the stock is currently owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Further Reading: Are all No-Load Funds Equal?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Expect Coeur Mining Inc  Will Post Earnings of -$0.07 Per Share
Brokerages Expect Coeur Mining Inc Will Post Earnings of -$0.07 Per Share
-$0.12 Earnings Per Share Expected for Ferroglobe PLC  This Quarter
-$0.12 Earnings Per Share Expected for Ferroglobe PLC This Quarter
Brokerages Anticipate Eastside Distilling Inc  Will Announce Earnings of -$0.19 Per Share
Brokerages Anticipate Eastside Distilling Inc Will Announce Earnings of -$0.19 Per Share
Nanometrics Incorporated  Expected to Announce Earnings of $0.21 Per Share
Nanometrics Incorporated Expected to Announce Earnings of $0.21 Per Share
-$0.08 Earnings Per Share Expected for ZIOPHARM Oncology Inc.  This Quarter
-$0.08 Earnings Per Share Expected for ZIOPHARM Oncology Inc. This Quarter
Short Interest in Unifi, Inc.  Drops By 7.6%
Short Interest in Unifi, Inc. Drops By 7.6%


© 2006-2019 Ticker Report